[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.238.168. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 879
Citations 0
News From the Food and Drug Administration
May 19, 2015

New Type of Drug for Heart Failure

JAMA. 2015;313(19):1898. doi:10.1001/jama.2015.4799

A newly approved heart failure drug that was fast-tracked by the FDA is the first in its class.

The FDA approved Amgen’s Corlanor in mid-April for certain patients with left ventricular heart failure. It is indicated for patients with stable symptoms and a normal heartbeat with a resting heart rate of at least 70 beats per minute who also take the highest dose of β-blockers they can tolerate.

In a clinical trial including 6505 patients, Corlanor reduced the risk of hospitalization for worsening heart failure compared with placebo. The most common adverse effects in the clinical trial were bradycardia, hypertension, atrial fibrillation, and temporary vision disturbances.

First Page Preview View Large
First page PDF preview
First page PDF preview
×